Once the hottest “baby‑face injection” has gone bankrupt

A one‑product bet unravels

Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. (江苏吴中医药发展股份有限公司) — a 1994‑founded, 1999‑listed old‑line drugmaker whose market value once peaked in the tens of billions of RMB — has been pushed to the brink of bankruptcy after a dramatic collapse of its medical‑aesthetic business. The Suzhou Intermediate People’s Court has accepted a bankruptcy petition against the company, following a risk alert from Jiangsu securities firms and a cascade of operational shocks. Can a single imported filler really carry an entire company? Wuzhong’s experience answers that question bluntly: no.

How the AestheFill (艾塑菲) boom turned bust

Wuzhong’s pivot to aesthetics looked promising in 2021, when the company paid to control the China distribution rights for Korean Regen Biotech’s AestheFill (艾塑菲), an imported poly‑L‑lactic acid “baby‑face” filler that briefly fueled rapid revenue growth and helped end years of losses. But the upstream landscape shifted: it has been reported that early in 2025 aesthetics leader Aimeike (爱美客) acquired an 85% stake in Regen, setting off a fight over distribution. Regen reportedly sent a termination letter to Wuzhong’s unit Dato Medical (达透医疗); Wuzhong filed arbitration seeking RMB 1.6 billion and briefly won temporary protections that were later revoked in January 2026. Once AestheFill sales ceased, Wuzhong’s revenue plunged and the company returned to losses.

Regulatory blows and broader industry lessons

The damage was compounded by a China Securities Regulatory Commission administrative ruling that found Wuzhong had concealed its actual controller, inflated revenues across related‑party trades and allowed massive non‑operating related‑party fund use — findings that led to its delisting from the Shanghai exchange and effectively destroyed investor confidence. This is more than a single corporate failure. It is a symptom of a wider consolidation in China’s rapidly maturing medical‑aesthetics market, where regulators are tightening oversight, upstream makers are reclaiming channels, and consumers and investors increasingly prize real R&D, compliant governance and in‑house brands over short‑lived import fads. The exit of Wuzhong is a cautionary tale: in today’s market, marketing alone will not substitute for structural depth.